StockWatch: Gene Editing Shares Jump on ESGCT Data, FDA Draft Guidance

T2Covered by 1 source · first reported by Fierce Biotech / Fierce Healthcare / MedCity / GEN at 01 Nov, 19:03 UTC

Shares of gene editing therapy companies mostly surged this past week on two growth catalysts: Data readouts at the European Society of Gene and Cell Therapy’s 33rd ESGCT Annual Congress, and the FDA's new draft guidance for personalized gene therapies. The post StockWatch: Gene Editing Shares Jump…

science

Sources

• T2StockWatch: Gene Editing Shares Jump on ESGCT Data, FDA Draft GuidanceFierce Biotech / Fierce Healthcare / MedCity / GEN01 Nov, 19:03